Abstract
The aim was to explore the antimicrobial activity of a synthetic peptide (AMP38) and its synergy with imipenem against imipenem-resistant Pseudomonas aeruginosa. The main mechanism of imipenem resistance is the loss or alteration of protein OprD. Time-kill and minimal biofilm eradication concentration (MBEC) determinations were carried out by using clinical imipenem-resistant strains. AMP38 was markedly synergistic with imipenem when determined in imipenem-resistant P. aeruginosa. MBEC obtained for the combination of AMP38 and imipenem was of 62.5 μg/mL, whereas the MBEC of each antimicrobial separately was 500 μg/mL. AMP38 should be regarded as a promising antimicrobial to fight MDR P. aeruginosa infections. Moreover, killing effect and antibiofilm activity of AMP38 plus imipenem was much higher than that of colistin plus imipenem.
Highlights
Pseudomonas aeruginosa is a nosocomial opportunistic pathogen causing a wide variety of both acute and chronic infections, such as pneumonia, bacteraemia, and urinary tract infections.Immunocompromised patients and those suffering cystic fibrosis show a high susceptibility to infection by this microorganism [1].the increasing frequency of the isolation of multidrug-resistant Pseudomonas aeruginosa (MDRPA) is a major cause for concern
The aim of this study was to explore the antimicrobial activity of a novel synthetic cyclolipopeptide analog of polymyxin (AMP38) and its synergy with carbapenems in order to contribute to the improvement of treatments for infections caused by carbapenem-resistant P. aeruginosa
When assays were performed with AMP38, the fractional inhibitory concentrations (FICs) index (FICi) value to be considered as indifferent
Summary
Pseudomonas aeruginosa is a nosocomial opportunistic pathogen causing a wide variety of both acute and chronic infections, such as pneumonia, bacteraemia, and urinary tract infections.Immunocompromised patients and those suffering cystic fibrosis show a high susceptibility to infection by this microorganism [1].the increasing frequency of the isolation of multidrug-resistant Pseudomonas aeruginosa (MDRPA) is a major cause for concern. Pseudomonas aeruginosa is a nosocomial opportunistic pathogen causing a wide variety of both acute and chronic infections, such as pneumonia, bacteraemia, and urinary tract infections. Immunocompromised patients and those suffering cystic fibrosis show a high susceptibility to infection by this microorganism [1]. Carbapenems— imipenem—are broad-spectrum antimicrobials commonly used for the treatment of MDRPA infections. Their mechanism of action is based in the inhibition of the third step of the synthesis of bacterial cell wall by binding to certain penicillin-binding proteins (PBPs)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
